Er is echter meer klinisch bewijs nodig
That is a treatment difference of 20 events per hour, representing approximately a 63% reduction in sleep apnea severity
Additionally, this treatment is not only for individuals with diabetes adults with type 2 diabetes often benefit from its blood sugar regulation properties, but it is also widely prescribed for weight loss in non-diabetic individuals
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
So, you can find me there